Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy
Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lu...
Ausführliche Beschreibung
Autor*in: |
Hutten, Ryan [verfasserIn] Surucu, Murat [verfasserIn] Joyce, Cara [verfasserIn] Alite, Fiori [verfasserIn] Stang, Kyle [verfasserIn] Small, Christina [verfasserIn] Sethi, Anil [verfasserIn] Emami, Bahman [verfasserIn] Harkenrider, Matthew M. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2018 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 7(2018), 1 vom: 18. Jan., Seite 63-67 |
---|---|
Übergeordnetes Werk: |
volume:7 ; year:2018 ; number:1 ; day:18 ; month:01 ; pages:63-67 |
Links: |
---|
DOI / URN: |
10.1007/s13566-018-0342-y |
---|
Katalog-ID: |
SPR031812821 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR031812821 | ||
003 | DE-627 | ||
005 | 20230519141842.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13566-018-0342-y |2 doi | |
035 | |a (DE-627)SPR031812821 | ||
035 | |a (SPR)s13566-018-0342-y-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Hutten, Ryan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. | ||
650 | 4 | |a Lung SBRT |7 (dpeaa)DE-He213 | |
650 | 4 | |a Radiation pneumonitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pneumonitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Conformality index |7 (dpeaa)DE-He213 | |
700 | 1 | |a Surucu, Murat |e verfasserin |4 aut | |
700 | 1 | |a Joyce, Cara |e verfasserin |4 aut | |
700 | 1 | |a Alite, Fiori |e verfasserin |4 aut | |
700 | 1 | |a Stang, Kyle |e verfasserin |4 aut | |
700 | 1 | |a Small, Christina |e verfasserin |4 aut | |
700 | 1 | |a Sethi, Anil |e verfasserin |4 aut | |
700 | 1 | |a Emami, Bahman |e verfasserin |4 aut | |
700 | 1 | |a Harkenrider, Matthew M. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of radiation oncology |d Berlin : Springer, 2012 |g 7(2018), 1 vom: 18. Jan., Seite 63-67 |w (DE-627)718611233 |w (DE-600)2660511-9 |x 1948-7908 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2018 |g number:1 |g day:18 |g month:01 |g pages:63-67 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13566-018-0342-y |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 7 |j 2018 |e 1 |b 18 |c 01 |h 63-67 |
author_variant |
r h rh m s ms c j cj f a fa k s ks c s cs a s as b e be m m h mm mmh |
---|---|
matchkey_str |
article:19487908:2018----::soitoocnomltidxnpstetetaitopemntsnalsaeosalelugacrr |
hierarchy_sort_str |
2018 |
publishDate |
2018 |
allfields |
10.1007/s13566-018-0342-y doi (DE-627)SPR031812821 (SPR)s13566-018-0342-y-e DE-627 ger DE-627 rakwb eng 610 ASE Hutten, Ryan verfasserin aut Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 Surucu, Murat verfasserin aut Joyce, Cara verfasserin aut Alite, Fiori verfasserin aut Stang, Kyle verfasserin aut Small, Christina verfasserin aut Sethi, Anil verfasserin aut Emami, Bahman verfasserin aut Harkenrider, Matthew M. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 7(2018), 1 vom: 18. Jan., Seite 63-67 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:7 year:2018 number:1 day:18 month:01 pages:63-67 https://dx.doi.org/10.1007/s13566-018-0342-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 7 2018 1 18 01 63-67 |
spelling |
10.1007/s13566-018-0342-y doi (DE-627)SPR031812821 (SPR)s13566-018-0342-y-e DE-627 ger DE-627 rakwb eng 610 ASE Hutten, Ryan verfasserin aut Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 Surucu, Murat verfasserin aut Joyce, Cara verfasserin aut Alite, Fiori verfasserin aut Stang, Kyle verfasserin aut Small, Christina verfasserin aut Sethi, Anil verfasserin aut Emami, Bahman verfasserin aut Harkenrider, Matthew M. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 7(2018), 1 vom: 18. Jan., Seite 63-67 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:7 year:2018 number:1 day:18 month:01 pages:63-67 https://dx.doi.org/10.1007/s13566-018-0342-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 7 2018 1 18 01 63-67 |
allfields_unstemmed |
10.1007/s13566-018-0342-y doi (DE-627)SPR031812821 (SPR)s13566-018-0342-y-e DE-627 ger DE-627 rakwb eng 610 ASE Hutten, Ryan verfasserin aut Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 Surucu, Murat verfasserin aut Joyce, Cara verfasserin aut Alite, Fiori verfasserin aut Stang, Kyle verfasserin aut Small, Christina verfasserin aut Sethi, Anil verfasserin aut Emami, Bahman verfasserin aut Harkenrider, Matthew M. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 7(2018), 1 vom: 18. Jan., Seite 63-67 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:7 year:2018 number:1 day:18 month:01 pages:63-67 https://dx.doi.org/10.1007/s13566-018-0342-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 7 2018 1 18 01 63-67 |
allfieldsGer |
10.1007/s13566-018-0342-y doi (DE-627)SPR031812821 (SPR)s13566-018-0342-y-e DE-627 ger DE-627 rakwb eng 610 ASE Hutten, Ryan verfasserin aut Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 Surucu, Murat verfasserin aut Joyce, Cara verfasserin aut Alite, Fiori verfasserin aut Stang, Kyle verfasserin aut Small, Christina verfasserin aut Sethi, Anil verfasserin aut Emami, Bahman verfasserin aut Harkenrider, Matthew M. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 7(2018), 1 vom: 18. Jan., Seite 63-67 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:7 year:2018 number:1 day:18 month:01 pages:63-67 https://dx.doi.org/10.1007/s13566-018-0342-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 7 2018 1 18 01 63-67 |
allfieldsSound |
10.1007/s13566-018-0342-y doi (DE-627)SPR031812821 (SPR)s13566-018-0342-y-e DE-627 ger DE-627 rakwb eng 610 ASE Hutten, Ryan verfasserin aut Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 Surucu, Murat verfasserin aut Joyce, Cara verfasserin aut Alite, Fiori verfasserin aut Stang, Kyle verfasserin aut Small, Christina verfasserin aut Sethi, Anil verfasserin aut Emami, Bahman verfasserin aut Harkenrider, Matthew M. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 7(2018), 1 vom: 18. Jan., Seite 63-67 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:7 year:2018 number:1 day:18 month:01 pages:63-67 https://dx.doi.org/10.1007/s13566-018-0342-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 7 2018 1 18 01 63-67 |
language |
English |
source |
Enthalten in Journal of radiation oncology 7(2018), 1 vom: 18. Jan., Seite 63-67 volume:7 year:2018 number:1 day:18 month:01 pages:63-67 |
sourceStr |
Enthalten in Journal of radiation oncology 7(2018), 1 vom: 18. Jan., Seite 63-67 volume:7 year:2018 number:1 day:18 month:01 pages:63-67 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Lung SBRT Radiation pneumonitis Pneumonitis Conformality index |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Journal of radiation oncology |
authorswithroles_txt_mv |
Hutten, Ryan @@aut@@ Surucu, Murat @@aut@@ Joyce, Cara @@aut@@ Alite, Fiori @@aut@@ Stang, Kyle @@aut@@ Small, Christina @@aut@@ Sethi, Anil @@aut@@ Emami, Bahman @@aut@@ Harkenrider, Matthew M. @@aut@@ |
publishDateDaySort_date |
2018-01-18T00:00:00Z |
hierarchy_top_id |
718611233 |
dewey-sort |
3610 |
id |
SPR031812821 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-018-0342-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-018-0342-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hutten, Ryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiation pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conformality index</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Surucu, Murat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joyce, Cara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, Fiori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stang, Kyle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, Christina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, Anil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, Bahman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">7(2018), 1 vom: 18. Jan., Seite 63-67</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:63-67</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-018-0342-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">01</subfield><subfield code="h">63-67</subfield></datafield></record></collection>
|
author |
Hutten, Ryan |
spellingShingle |
Hutten, Ryan ddc 610 misc Lung SBRT misc Radiation pneumonitis misc Pneumonitis misc Conformality index Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
authorStr |
Hutten, Ryan |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718611233 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1948-7908 |
topic_title |
610 ASE Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy Lung SBRT (dpeaa)DE-He213 Radiation pneumonitis (dpeaa)DE-He213 Pneumonitis (dpeaa)DE-He213 Conformality index (dpeaa)DE-He213 |
topic |
ddc 610 misc Lung SBRT misc Radiation pneumonitis misc Pneumonitis misc Conformality index |
topic_unstemmed |
ddc 610 misc Lung SBRT misc Radiation pneumonitis misc Pneumonitis misc Conformality index |
topic_browse |
ddc 610 misc Lung SBRT misc Radiation pneumonitis misc Pneumonitis misc Conformality index |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of radiation oncology |
hierarchy_parent_id |
718611233 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Journal of radiation oncology |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)718611233 (DE-600)2660511-9 |
title |
Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
ctrlnum |
(DE-627)SPR031812821 (SPR)s13566-018-0342-y-e |
title_full |
Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
author_sort |
Hutten, Ryan |
journal |
Journal of radiation oncology |
journalStr |
Journal of radiation oncology |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2018 |
contenttype_str_mv |
txt |
container_start_page |
63 |
author_browse |
Hutten, Ryan Surucu, Murat Joyce, Cara Alite, Fiori Stang, Kyle Small, Christina Sethi, Anil Emami, Bahman Harkenrider, Matthew M. |
container_volume |
7 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Hutten, Ryan |
doi_str_mv |
10.1007/s13566-018-0342-y |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
title_auth |
Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
abstract |
Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. |
abstractGer |
Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. |
abstract_unstemmed |
Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy |
url |
https://dx.doi.org/10.1007/s13566-018-0342-y |
remote_bool |
true |
author2 |
Surucu, Murat Joyce, Cara Alite, Fiori Stang, Kyle Small, Christina Sethi, Anil Emami, Bahman Harkenrider, Matthew M. |
author2Str |
Surucu, Murat Joyce, Cara Alite, Fiori Stang, Kyle Small, Christina Sethi, Anil Emami, Bahman Harkenrider, Matthew M. |
ppnlink |
718611233 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s13566-018-0342-y |
up_date |
2024-07-04T01:21:12.035Z |
_version_ |
1803609515795415040 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-018-0342-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-018-0342-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hutten, Ryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association of conformality index and post-treatment radiation pneumonitis in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Conformality index of the 50% prescription isodose volume (CI50) is an important variable in lung stereotactic body radiotherapy (SBRT) planning but has not been previously correlated to radiation pneumonitis (RP). We hypothesized that adherence to recommended CI50 for patients undergoing lung SBRT would result in decreased incidence and/or severity of RP compared to that for patients with minimal deviations and unacceptable deviations. Methods and materials We retrospectively identified patients treated between 2006 and 2016, with > 3 months follow up from lung SBRT treatment. CTCAE v4.0 toxicity grades were used to classify RP. Clinically significant RP was defined as grade ≥ 2 toxicity. Using Radiation Therapy Oncology Group CI50 planning guidelines, patients were separated into three groups: acceptable, minor deviation, and unacceptable deviation. CI25 and CI75 values in patients with and without clinically significant RP were also reported in this study. Results One hundred seventy-four patients with a median follow-up time of 26.8 months were included in this analysis. Overall incidence of grade ≥ 2 RP was 12.7%. Thirty-eight (21.8%) patients had acceptable CI50, 100 (57.5%) had minor deviations, and 36 (20.7%) had unacceptable deviations. Incidence of RP did not significantly differ between patients with acceptable, minor deviation, and unacceptable CI50. Additionally, CI25 and CI75 did not significantly differ between patients with and without clinically significant RP. Conclusions Adhering to recommended CI50 values does not significantly decrease the incidence of clinically significant RP in patients with NSCLC treated with SBRT. To the authors’ knowledge, this observation has not been published previously.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiation pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conformality index</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Surucu, Murat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joyce, Cara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, Fiori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stang, Kyle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, Christina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, Anil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, Bahman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">7(2018), 1 vom: 18. Jan., Seite 63-67</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:63-67</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-018-0342-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">01</subfield><subfield code="h">63-67</subfield></datafield></record></collection>
|
score |
7.4001493 |